Morgan Stanley analyst Matthew Harrison started Moderna with an Overweight rating and $29 price target, stating that he currently models peak, risk-adjusted sales of $8B, with prophylactic vaccines, rare diseases and cancer vaccines driving the bulk of that. However, Harrison added that the company’s broad pipeline includes 21 programs and if the entire pipeline were to be successful he believes peak sales could be as high as about $35B.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.